Category: News

Ocular Therapeutix™ Announces Successful Topline Results for Both Inflammation and Pain Primary Efficacy Endpoints from Phase 3 Clinical Trial of DEXTENZA™

BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced positive topline results from its phase 3 clinical trial of DEXTENZA™ (dexamethasone insert) 0.4 mg, for the treatment of post-surgical ocular inflammation and pain. DEXTENZA is a product candidate administered by a physician as a bioresorbable intracanalicular insert


Neue bahnbrechende Studie belegt Vermeidbarkeit von Sehverlust bei Erwachsenen mit Diabetes

NEWBURY, England–(BUSINESS WIRE)–Obwohl die Angst vor Sehverlust doppelt so hoch ist wie die Angst vor anderen häufigen mit Diabetes verbundenen Komplikationen (einschließlich Herzkreislauferkrankungen und Schlaganfall), bespricht ein Viertel der befragten Patienten mit Diabetes das Thema Augenkomplikationen nicht mit medizinischem Fachpersonal, während viele erst ärztlichen Rat suchen, wenn Sehkraftprobleme bereits vorhanden sind.1 Dies sind einige der besorgniserregenden Erkenntnisse aus de


Tobii Pro Launches Pioneering Eye Tracker and Biometric Software Platform for Behavioral Research

STOCKHOLM–(BUSINESS WIRE)–Tobii Pro (STO:TOBII), the global leader in eye tracking research solutions, continues to push the envelope in eye tracking innovation with the launch of Tobii Pro Spectrum and Tobii Pro Lab, its most advanced eye tracking solutions to date. These research tools – to be exhibited at Neuroscience 2016 (https://www.sfn.org/annual-meeting/neuroscience-2016) in San Diego, Calif. – from November 12-16 – will further expand the scope and richness of what can be achieved in


Castle Biosciences Announces Data Presentation at the Society for Melanoma Research 2016 Congress Demonstrating Clinical Impact of DecisionDx-Melanoma Test Results on Patient Management

FRIENDSWOOD, Texas–(BUSINESS WIRE)–Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced results from a study evaluating the clinical impact of its gene expression profile (GEP) test DecisionDx®-Melanoma on patient management decisions. The test uses tumor biology to provide an individual risk of recurrence in cutaneous (skin) melanoma patients. The data were presented in a poster session at the Society for Melanoma Research 2016